Holaira is developing a catheter-based system to address chronic obstructive pulmonary disease (COPD) by treating the overactive airway nerves in a procedure called Targeted Lung Denervation (TLD). Similar to anticholinergic drugs, TLD targets the parasympathetic innervation of the lungs [1]. This one-time bronchoscopic procedure provides an ablative therapy that opens obstructed airways to improve breathing and has the potential to provide lasting whole lung improvement. Targeted Lung Denervation is currently under clinical investigation for chronic obstructive pulmonary disease and is not yet commercially available.